52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Gilead Sciences Reports Q3 Non-GAAP Earnings Per Share Of $2.11
Gilead Sciences Says FDA Approved Antiviral Veklury (Remdesivir) For COVID-19
FDA Says Remdesivir EUA Letter Of Authorization, Reissued Oct 16
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Biotechnology & Drugs
333 LAKESIDE DR
FOSTER CITY, CA
Chairman of the Board, Chief Executive Officer
Andrew D. Dickinson
Chief Financial Officer, Executive Vice President
Brett Alan Pletcher
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President of Human Resources
Senior Vice President - Head of External Innovation
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The White House coronavirus task force warned that much of the country is in the grips of an "unrelenting" surge in COVID-19 cases and urged tough countermeasures, as the number of U.S. infections reported on Thursday hit a new daily record of more than 91,000.
Gilead Sciences Inc <GILD.O> on Wednesday cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with COVID-19.
Gilead Sciences Inc reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.
Shares of Gilead Sciences Inc rose 6% on Friday after its antiviral drug, remdesivir, became the first and only approved treatment for COVID-19 in the United States.
The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Gilead Sciences Inc's remdesivir is at the forefront in the fight against the novel coronavirus as one of the first drugs to have shown to be effective in countering COVID-19 in human trials. On Thursday, the U.S. Food and Drug Administration approved remdesivir for treating...
The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's remdesivir (Veklury). (Reporting by Vishwadha Chander in Bengaluru; Editing by Maju Samuel)
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
The European Union should renegotiate a 1 billion euro ($1.2 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.
A row broke out on Friday over a World Health Organization (WHO) clinical trial which concluded that the anti-viral drug remdesivir has little or no impact on a patient's chances of surviving COVID-19.
The World Health Organization said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID-19 treatments, after the trial found Gilead Science's remdesivir had no impact on survival rates.
The European Union should renegotiate a 1 billion euro ($1.17 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.
Gilead Sciences Inc <GILD.O> has questioned the findings of a World Health Organization (WHO) study that concluded its COVID-19 drug remdesivir does not help patients who have been admitted to hospital.
A World Health Organization (WHO) trial that concluded Gilead Sciences Inc. remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated it said on Friday, as the U.S. company criticized its methodology.
* GILEAD SAYS ARE CONCERNED THAT THE DATA FROM THE OPENLABEL GLOBAL TRIAL HAVE NOT UNDERGONE RIGOROUS REVIEW
Gilead Sciences Inc's remdesivir had no substantial effect on COVID-19 patients' chances of survival, a clinical trial by the World Health Organization (WHO) has found, the Financial Times reported on Thursday.
The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency's program to identify promising drugs to help tackle the new coronavirus.
The European Union has agreed to pay more than 1 billion euros ($1.2 billion) to Gilead <GILD.O> for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication.
Final data from Gilead Sciences Inc's <GILD.O> antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said on Thursday.
A late-stage trial testing the combination of Gilead Sciences' remdesivir and a highly concentrated solution of antibodies that neutralize the COVID-19 virus has begun, the National Institutes of Health (NIH) said on Thursday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.